Edwards Lifesciences Corp
SWB:EWL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Edwards Lifesciences Corp
SWB:EWL
|
US |
Intrinsic Value
The intrinsic value of 
Edwards Lifesciences Corp (EWL) under the Base Case is 60.58 EUR per share.
Compared with the current market price of 73.12 EUR, the stock appears
Overvalued by 17% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Edwards Lifesciences Does
Edwards Lifesciences makes medical devices for people with serious heart disease. Its main products are replacement heart valves, including minimally invasive valves that can be delivered through a catheter instead of open-heart surgery, plus monitoring tools used in intensive care and during surgery. The company focuses on conditions where the heart cannot pump or valve properly, so its products help doctors treat patients with structural heart disease and monitor them closely in the hospital.
- Headquarters
- United States of America US
- Employees
- 16 000
- IPO date
- Mar 27, 2000
Edwards Lifesciences has a narrow economic moat
Protected valve technology, demanding approval requirements and the time doctors spend learning Edwards’ devices make it difficult for rivals to win business on price alone. These barriers provide lasting protection, although established competitors such as Medtronic and Abbott offer alternatives.
Read the full moat analysis
Revenue & Expenses Breakdown
Edwards Lifesciences Corp
Earnings Waterfall
Edwards Lifesciences Corp
The intrinsic value for Edwards Lifesciences Corp (EWL) under the Base Case is 60.58 EUR.
Compared with the current market price of 73.12 EUR, the stock appears Overvalued by 17% .